Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
April 27 2023 - 08:05AM
GlobeNewswire Inc.
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in retinal
indications, today announced that Russ Trenary, President and Chief
Executive Officer and Glen Olsheim as Executive Director,
Commercial Excellence of Outlook Therapeutics will participate
in a fireside chat at the H.C. Wainwright BioConnect Investor
Conference at Nasdaq on Tuesday, May 2, 2023 at 2:00 PM ET.
In addition to the presentation, management will
be available to participate in one-on-one meetings with qualified
members of the investor community who are registered to attend the
conference.
A live video webcast of the fireside chat will
be accessible on the Events page in the Investors section of the
Company’s website (outlooktherapeutics.com). The webcast replay
will be archived for 90 days following the event.
About Outlook Therapeutics,
Inc.Outlook Therapeutics is a biopharmaceutical company
working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission
for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29,
2023. The submission is supported by Outlook Therapeutics’ wet AMD
clinical program, which consists of three clinical trials: NORSE
ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab
is approved, Outlook Therapeutics expects to commercialize it as
the first and only FDA-approved ophthalmic formulation of
bevacizumab for use in treating retinal diseases in the United
States, United Kingdom, Europe, Japan, and other markets. As part
of the Company’s multi-year commercial planning process, and in
anticipation of potential FDA approval in August 2023, Outlook
Therapeutics and AmerisourceBergen have entered into a strategic
commercialization agreement to expand the Company’s reach for
connecting to retina specialists and their patients.
AmerisourceBergen will provide third-party logistics (3PL) services
and distribution, as well as pharmacovigilance and other services
in the United States. For more information, please
visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice President LaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor Inquiries:Jenene ThomasChief Executive
OfficerJTC Team, LLCT: 833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Aug 2023 to Sep 2023
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Sep 2022 to Sep 2023